Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lingbao Huxin Dan for stable coronary heart disease (Qi-deficiency and blood-stasis type)
ChiCTR2300068806Phase 4Recruiting
- Sponsor
- Beijing University of Chinese Medicine Third Affiliated Hospital
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Lingbao Huxin Dan in coronary arteriosclerosis and angina pectoris (2 arms), sponsored by Beijing University of Chinese Medicine Third Affiliated Hospital. Primary endpoints: Chinese Medicine Symptom Score and Angina efficacy score. Started Oct 2022; status: recruiting.
02
Drugs
Lingbao Huxin Dan
03
Conditions
coronary arteriosclerosisangina pectoris
Beyond the preview
Go deeper on ChiCTR2300068806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068806.